FindTrial
Sign In

Acupuncture for lower limb rigidity in early and middle stage of Parkinson's disease: A single blind randomized clinical trial

Acupuncture for lower limb rigidity in early and middle stage of Parkinson's disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200061656
Enrollment
Unknown
Registered
2022-06-30
Start date
2021-07-01
Completion date
Unknown
Last updated
2024-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

Treatment group:Anti Parkinson drugs + acupuncture
control group:Anti Parkinson drugs + sham acupuncture

Sponsors

The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of Parkinson's disease; 2. Aged 40-75 years; 3. Ashworth scale score of lower limb rigidity is grade 1.5 or above; 4. No acupuncture treatment was received within 3 months before enrollment; 5. The anti PD drug regimen was not adjusted within 1 months before enrollment; 6. According to Hoehn Yahr classification, the severity of the disease is 1 ~ 3, that is, patients with early and middle stage of Parkinson's disease; 7. Be aware, sign the informed consent form, agree to accept the treatment method and course of this study, and be willing to cooperate to fill in the scoring scale.

Exclusion criteria

Exclusion criteria: 1. Accompanied by significant fluctuations in Parkinson's motor symptoms or motor complications; 2. UPDRS Part 4 score greater than or equal to 1 point; 3. Patients who are unable to regularly take anti Parkinson's drugs; 4.Combined organic diseases of lower limb joints; 5. Combined diseases that seriously affect motor function such as gout; 6.Patients with severe complications, senile psychosis, epilepsy, serious organ diseases such as heart, lung, liver and kidney, endocrine and metabolic diseases and malignant tumors; 7. Subjects participating in other clinical trials at the same time.

Design outcomes

Primary

MeasureTime frame
Unified Parkinson’s Disease Rating Scale III;—

Secondary

MeasureTime frame
Gait monitoring;Ashworth scale;Falls Efficacy Scale;Self-percrived burden Scale;Parkinson's Disease Questionnaire (PDQ-39);Hamilton anxiety scale;Unified Parkinson’s Disease Rating Scale;—

Countries

China

Contacts

Public ContactZhuang Lixing

Guangzhou University of Traditional Chinese Medicine

zhuanglixing@163.com+86 138 2228 7775

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026